”Regenerative Medicine: Highlighting and Correcting Misinformation” - discussion topic from Rice University Baker Institute’s Annual Event, featuring presentation by cardiologist scientist Dr. Emerson Perin of Texas Heart Institute, Principal Investigator of Mesoblast’s DREAM-Heart Failure Phase 3 trial on patients with advanced stage 2 and 3 heart failure. The results show how the company’s Rexlemetrocel product works amazingly on patients with high inflammation biomarkers.
Video on page as you scroll down discusses the trial.
https://www.texasheart.org/rice-universitys-baker-institute-for-public-policy-hosts-6th-annual-regenerative-medicine-discussion/
”Regenerative Medicine: Highlighting and Correcting...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |